John Cole

SimBioSys announced today it raised $15 million in Series A funding to accelerate the development and commercialization of its TumorScope software platform. The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients.

This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic. Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21 million.

The IGB’s Fox Family Innovation and Entrepreneurship Certificate Program has inspired one participant to found a company with a mission to create computational tools for biomedical researchers.

Maybe it’s not such a dog-eat-dog world after all. A clever combination of two different types of computer simulations enabled a group of Illinois researchers to uncover an unexpectedly cooperative group dynamic: the spontaneous emergence of resource sharing among individuals in a community.  Who were the members of this friendly, digitally represented collective?  Escherichia coli, rod-shaped bacteria found in the digestive systems of humans and many other animals.